Abstract
This large retrospective dataset unequivocally confirmed the survival advantage afforded by cytarabine-containing regimens and autologous stem cell transplantation (ASCT) in a first-line setting under real-world management in the rituximab era.
Introduction
Mantle Cell Lymphoma (MCL) is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma. While clinical trials have established "gold standard" treatments—specifically the inclusion of the anti-CD20 antibody rituximab and intensive chemotherapy—real-world application often lags behind, particularly in diverse geographic regions.
In China, the clinical landscape for MCL differs from Western nations. The incidence is lower, and patient characteristics, such as a younger median age and a higher prevalence of comorbidities like Hepatitis B, are distinct. Furthermore, economic factors and local medical practices significantly influence treatment accessibility. This study addresses the critical lack of large-scale, real-world data regarding the management of Chinese MCL patients and evaluates whether Western intensive therapy standards effectively translate to improved survival outcomes in this population.
Methods
Researchers conducted a retrospective multicenter study involving 518 newly diagnosed MCL patients treated at five major Chinese academic hematology centers (Beijing, Guangzhou, Nanjing, Shanghai, and Suzhou) between 2007 and 2017.
Survival analysis was performed using the Kaplan–Meier method to estimate overall survival (OS), with log-rank tests employed to compare differences between treatment groups. To identify independent prognostic factors, the team utilized Cox proportional hazards models for both univariate and multivariate analyses. This cohort represents the largest Chinese MCL dataset analyzed to date, providing a vital regional baseline for comparison with established Western registries.
Key Insights and Treatment Outcomes
Demographic Shifts
A notable finding was the younger demographic of the Chinese cohort. The median age was 58 years, significantly lower than the 65–70 years typically observed in Western populations. This suggests potential differences in biological drivers or environmental factors, or perhaps earlier clinical presentation.
The Impact of Intensive Therapy
The study demonstrated a clear survival advantage for patients receiving intensive frontline therapies. High-dose cytarabine-containing regimens and consolidative ASCT were both associated with superior outcomes. For instance, younger patients who underwent ASCT achieved a 5-year OS of 87.2%, compared to 64.8% for those who did not.
Despite these benefits, ASCT remains heavily underutilized in China. Only 13.7% of the total cohort (and 22% of eligible younger patients) received the procedure, a rate significantly lower than the 30%+ often reported in Western real-world studies. Barriers such as cost, limited local expertise, and patient preference likely contribute to this gap.
The Rituximab Paradox
Interestingly, the impact of rituximab on 5-year OS showed only borderline significance ($p = 0.076$). The authors attribute this to the late inclusion of rituximab in national insurance (2017), which often led to fewer treatment cycles due to high out-of-pocket costs. Additionally, the high prevalence of Hepatitis B in China complicates the use of rituximab, requiring careful monitoring and prophylaxis.
Prognostic Factors and Survival
The 3-year and 5-year OS rates for the entire cohort were 73.7% and 61.4%, respectively. Multivariate analysis identified several independent predictors of poor survival:
- High-risk MIPI score (Hazard Ratio [HR] = 2.32)
- Ki67 expression ≥ 30% (HR = 2.11)
- Lack of rituximab (HR = 0.55 for those receiving it)
- Lack of high-dose cytarabine (HR = 0.50 for those receiving it)
Conclusion and Future Directions
This study confirms that intensive first-line therapy—specifically high-dose cytarabine and ASCT—significantly improves survival for Chinese MCL patients in the rituximab era. However, the data also highlights a critical need for broader access to these therapies.
While the study is limited by its retrospective nature and the lack of "watch-and-wait" data, it underscores the importance of integrating novel agents (like ibrutinib or bortezomib) into frontline regimens. Future research should focus on optimizing strategies for elderly patients who cannot tolerate intensive chemotherapy and improving the utilization of consolidative therapies to bridge the survival gap between regional and global standards.
Summary updated